US · SHPH
Shuttle Pharmaceuticals Holdings, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Gaithersburg, MD 20850
- Website
- shuttlepharma.com
Price · as of 2024-12-31
$0.69
Market cap 1.07M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | $276.00 | ||||
| 2023 | $83.60 | ||||
| 2024 | $12.12 |
AI valuation
Our deep-learning model estimates Shuttle Pharmaceuticals Holdings, Inc.'s (SHPH) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.69
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SHPH | Shuttle Pharmaceuticals H… | $0.69 | 1.07M | — | — | — | — | -13.69 | 176.53 | — | -16.00 | -0.01 | 176.53 | 0.00% | — | — | -383.84% | 4303.31% | -216.24% | 1.65 | -5.66 | 1.44 | 1.25 | 0.10 | 21593171.00% | — | 3084.00% | -5.85% | -4.78 | 4097.02% | 0.00% | 0.00% | 0.00% | -16.17 | -16.98 | — | 12.67 |
| AKAN | Akanda Corp. | $1.04 | 151.47K | +9,512% | +862% | — | +18,953% | -6.36 | 6.09 | 31.14 | -7.45 | — | 6.11 | 24.91% | -523.80% | -489.57% | -1830.03% | -998.53% | -48.90% | 0.08 | -43.78 | 1.39 | 1.28 | 1.15 | -9355.00% | -6127.00% | 30467.00% | -23.33% | -1.09 | -1384.96% | 0.00% | 0.00% | 28.41% | -5.15 | -3.71 | 26.97 | -7.37 |
| BBLG | Bone Biologics Corporatio… | $1.15 | 2.07M | — | — | — | — | -1.86 | 2.19 | — | 40.32 | — | 2.19 | 0.00% | — | — | -128.71% | -22020.98% | -108.23% | 0.00 | — | 10.22 | 8.80 | -31.03 | -8580.00% | — | -5683.00% | -53.95% | -10.92 | -21530.04% | 42.02% | -78.10% | 45.92% | -1.02 | -1.05 | — | -21.20 |
| BIVI | BioVie Inc. | $1.38 | 10.41M | — | — | — | — | -0.15 | 0.14 | — | 0.86 | — | 0.14 | 0.00% | — | — | -101.64% | 8838.56% | -75.01% | 0.02 | -54.30 | 9.10 | 8.64 | 1.01 | -8341.00% | — | -3192.00% | -740.10% | -8.36 | 9307.74% | 0.00% | 0.00% | 0.00% | 0.81 | 0.77 | — | -24.00 |
| HSCS | HeartSciences Inc. | $2.79 | 6.25M | +699% | -40% | — | +21,742% | -0.45 | 19.02 | 897.28 | -0.71 | — | -2.77 | -2884.71% | -192013.13% | -201499.52% | -233.04% | -360.16% | -127.72% | 14.55 | -16.69 | 0.59 | 0.30 | -0.23 | -5016.00% | -7661.00% | 2014.00% | -190.70% | -2.00 | -320.95% | 0.00% | 0.00% | 0.00% | -0.69 | -0.78 | 1331.10 | -31.62 |
| IMCC | IM Cannabis Corp. | $0.68 | 2.1M | +52,536% | +13% | — | — | -0.54 | 1.20 | 0.12 | -3.82 | -39.70 | -1.32 | 15.64% | -18.94% | -19.59% | -119.43% | -38.57% | -26.75% | 3.44 | -2.29 | 0.67 | 0.50 | -2.79 | 135.00% | 1071.00% | -8576.00% | -19.57% | -0.03 | -5.05% | 0.00% | 0.00% | 0.00% | -2.29 | -19.02 | 0.43 | -8.98 |
| ISPC | iSpecimen Inc. | $0.25 | 1.39M | +15,728% | +124% | — | — | -0.08 | 0.30 | 0.11 | 0.04 | — | -0.50 | 42.93% | -136.99% | -134.51% | -191.51% | -381.28% | -99.31% | 0.09 | -57.84 | 0.62 | 0.58 | 0.12 | -2839.00% | -642.00% | -2115.00% | -830.12% | -1.43 | -249.24% | 0.00% | 0.00% | 0.00% | 0.04 | 0.07 | -0.06 | -14.44 |
| MSPR | MSP Recovery, Inc. | $0.04 | 537.2K | +14,182% | +17,977% | — | — | -0.01 | 0.14 | 0.76 | -1.22 | -0.01 | -0.01 | 47.36% | -6982.79% | -1975.45% | -834.83% | -139.81% | -61.30% | 7.90 | -3.03 | 0.01 | 0.01 | -1.20 | 12779.00% | 13685.00% | -6014.00% | -119.26% | -0.01 | -1.83% | 0.00% | 0.00% | 0.00% | -0.62 | -47.84 | 43.63 | -3.28 |
| RDHL | RedHill Biopharma Ltd. | $0.97 | 3.23M | +40,100% | +30% | — | — | -0.94 | -1.66 | 0.97 | -0.46 | — | -0.76 | 60.31% | -181.69% | -102.80% | 632.60% | 242.32% | -40.24% | -0.08 | -265.69 | 0.54 | 0.37 | 0.56 | -11522.00% | 2317.00% | -7383.00% | -120.72% | -0.42 | 155.51% | 0.00% | 0.00% | 0.00% | -0.24 | -0.37 | 0.44 | -34.89 |
| UPC | Universe Pharmaceuticals … | $2.72 | 1.53M | +5,735,314% | +242,398% | +399,145% | +515,984% | 0.00 | 0.00 | 0.00 | 8.32 | — | 0.00 | 35.28% | -16.33% | -20.56% | -7.23% | -10.45% | -5.35% | 0.16 | -12.57 | 4.07 | 3.55 | 8.33 | -2649.00% | -2244.00% | -4529.00% | -37140.54% | -0.38 | -19.36% | 0.00% | 0.00% | 19477.17% | 8.34 | 4.50 | -1.36 | 0.54 |
About Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
- CEO
- Christopher Robert Cooper
- Employees
- 9
- Beta
- 0.46
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.69) − 1 = — (DCF, example).